PTC Therapeutics

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

 
Press Releases
  Date Title and Summary View
Jun 13, 2016
SOUTH PLAINFIELD, N.J., June 13, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Dawn Svoronos to the company's Board of Directors. Ms. Svoronos most recently served as President of Merck's Europe/Canada region from 2009 to 2011 and as President of Merck in Canada from 2006 to 2009. "We are thril...
Jun 10, 2016
SOUTH PLAINFIELD, N.J., June 10, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that new analyses from the company's previous Phase 3, double-blind, placebo-controlled, 48-week 009 trial of Translarna™ (ataluren) for the treatment of nonsense mutation cystic fibrosis (caused by at least one nonsense mutation) are b...
May 16, 2016
SOUTH PLAINFIELD, N.J., May 16, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) is pleased to announce the recipients of the Company's global STRIVE Awards (Strategies to Realize Innovation, Vision and Empowerment) program, designed to support nonprofit organizations serving the cystic fibrosis (CF) community. The announcement coincides ...
May 5, 2016
SOUTH PLAINFIELD, N.J., May 5, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the first quarter ending March 31, 2016. "We are working hard to make Translarna available to all Duchene muscular dystrophy patients globally who may benefit," said Stuart W. Peltz,...
Apr 26, 2016
SOUTH PLAINFIELD, N.J., April 26, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Tuyen Ong, M.D. has been promoted to Chief Medical Officer. Dr. Ong joined PTC in 2014 as the Senior Vice President, Head of Clinical Development and Translational Research.  He succeeds Robert J. Spiegel M.D., FACP, who has served as P...
Apr 22, 2016
SOUTH PLAINFIELD, N.J., April 22, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 22, 2016 it approved non-statutory stock options to purchase an aggregate of 26,000 shares of its common stock to 4 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our new...
Apr 21, 2016
SOUTH PLAINFIELD, N.J., April 21, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter financial results and provide an update on the company's business and outlook on Thursday, May 5, 2016 at 4:30 p.m. (ET) after the closing of the market. ...
Apr 15, 2016
SOUTH PLAINFIELD, N.J., April 15, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the National Institute for Health and Care Excellence (NICE) has recommended Translarna ∇ (ataluren) for ambulatory patients aged five years and older with nonsense mutation Duchenne muscular dystrophy (nmDMD) in connection with ...
Mar 23, 2016
SOUTH PLAINFIELD, N.J., March 23, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company is reducing its workforce by approximately 18%, which will primarily affect employees and contractors in the U.S.  This reduction is part of PTC's program intended to optimally manage operating expenses following its recent ...
Mar 14, 2016
SOUTH PLAINFIELD, N.J., March 14, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company intends to submit the results of the recently completed Phase 3 ACT DMD study for review by Health Canada as part of the New Drug Submission (NDS) for Translarna™ (ataluren) to treat nonsense mutation Duchenne muscular...
Page:
1
... NextLast
= add release to Briefcase
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue